Finding ways to reduce heart damage from cancer treatments
Official title: Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics
Funded at Ohio State University · NIH-11002683 · Data updated 2026-11-12
This study is looking at ways to protect your heart from damage while you receive doxorubicin, a common chemotherapy drug for cancer, by figuring out how the drug gets into heart cells and finding ways to keep your heart safe during treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | January 1, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $671,704 |
| NIH project number | 5R01HL168045-02 |
| Project ID | NIH-11002683 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are being treated with anthracycline-based chemotherapy and are at risk of developing heart-related side effects.
✕Less likely to help
Patients who are not receiving anthracycline-based chemotherapy or those without a risk of cardiotoxicity may not benefit from this research.
What this research studies
This research investigates how to prevent heart damage caused by anthracycline-based chemotherapy, particularly doxorubicin, which is commonly used to treat various cancers. The study focuses on understanding how doxorubicin enters heart cells and identifying a specific transporter, OCT3, that plays a crucial role in this process. By using human stem cell-derived heart cells from cancer patients, the researchers aim to develop strategies that can protect the heart while still allowing the chemotherapy to effectively target cancer cells. The ultimate goal is to create a treatment approach that minimizes harmful side effects for patients undergoing cancer therapy.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments with reduced risk of heart damage for patients receiving anthracycline therapies.
How similar studies have gone: Previous research has shown promise in targeting similar transport mechanisms to mitigate drug-related toxicities, suggesting that this approach could be effective.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Sparreboom, Alexander — Ohio State University
- Study coordinator: Sparreboom, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.